Abstract PR06: Targeted chemotherapy for Homologous Repair Defects (HRD) in molecularly profiled cancer patients

Precision Medicine Tumor Boards (PMTB) are now established at many academic institutions and provide a forum for multidisciplinary teams to discuss tumor profiling results to aid treatment choices for cancer patients. PMTBs typically focus on kinase mutations and well defined translocations, mostly because of limited gene panels explored. Established treatments exist for some of these genetic aberrations and multiple clinical trials have been initiated for specific kinase-targeted investigational drugs in development.The Yale 409 Gene Panel (Ion Torrent; AmpliSeq Comprehensive Cancer Panel) includes a large set of Homologous Recombinant Deficiencies (HRD) related genes. HRD have been found in ~ 25 % of patient tumors molecularly profiled at the Yale Cancer Center PMTB. Mutations in HRD related genes often occur in addition to other mutations in signaling pathways, including many kinases. Specific targeted treatment options for these patients are limited, as currently only one drug, olaparib, is approved for patients with BRCA1/2 mutations in serous ovarian cancer. A number of other drugs are in development, but few clinical studies based on HRD other than BRCA1/2 mutations are open and HRD related genes are not always part of the cancer mutation panels that are the basis for PMTBs.The OLAParib COmbinations (OLAPCO) study was designed to develop therapeutic protocols for HRD in patients, irrespective of tumor origin. The protocol includes four initial arms, to which patients c...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Other Topics: Oral Presentations - Proffered Abstracts Source Type: research